Nurix Therapeutics, Inc. (NRIX)
15.49
-0.15
(-0.96%)
USD |
NASDAQ |
Feb 18, 16:00
15.75
+0.26
(+1.68%)
After-Hours: 20:00
Nurix Therapeutics EPS Diluted (Quarterly) : -0.8226 for Nov. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 7.857 |
| Incyte Corp. | 1.462 |
| Madrigal Pharmaceuticals, Inc. | -5.079 |
| SELLAS Life Sciences Group, Inc. | -0.0626 |
| Arcturus Therapeutics Holdings, Inc. | -0.4946 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -78.22M |
| Revenue (Quarterly) | 13.58M |
| Total Expenses (Quarterly) | 91.80M |
| Enterprise Value | 1.071B |
| Gross Profit Margin (Quarterly) | 65.89% |
| Profit Margin (Quarterly) | -576.1% |
| Earnings Yield | -19.64% |
| Normalized Earnings Yield | -19.64 |